These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 1948135

  • 1. Sequential chemoimmunotherapy for metastatic melanoma.
    Richards JM.
    Semin Oncol; 1991 Oct; 18(5 Suppl 7):91-5. PubMed ID: 1948135
    [Abstract] [Full Text] [Related]

  • 2. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
    Dillman RO, Soori G, Wiemann MC, Schulof R, Dobbs TW, Ruben RH, DePriest CB, Church C.
    Cancer Biother Radiopharm; 2000 Oct; 15(5):487-94. PubMed ID: 11155820
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
    Atzpodien J, Lopez Hänninen E, Kirchner H, Franzke A, Körfer A, Volkenandt M, Duensing S, Schomburg A, Chaitchik S, Poliwoda H.
    Eur J Cancer; 1995 Jun; 31A(6):876-81. PubMed ID: 7646914
    [Abstract] [Full Text] [Related]

  • 5. Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma.
    Thompson JA, Gold PJ, Markowitz DR, Byrd DR, Lindgren CG, Fefer A.
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S29-34. PubMed ID: 9457390
    [Abstract] [Full Text] [Related]

  • 6. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.
    Rusthoven JJ, Quirt IC, Iscoe NA, McCulloch PB, James KW, Lohmann RC, Jensen J, Burdette-Radoux S, Bodurtha AJ, Silver HK, Verma S, Armitage GR, Zee B, Bennett K.
    J Clin Oncol; 1996 Jul; 14(7):2083-90. PubMed ID: 8683240
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.
    Keilholz U, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, Thomas J, Proebstle TM, Schmittel A, Schadendorf D, Velu T, Negrier S, Kleeberg U, Lehman F, Suciu S, Eggermont AM.
    J Clin Oncol; 2005 Sep 20; 23(27):6747-55. PubMed ID: 16170182
    [Abstract] [Full Text] [Related]

  • 13. A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
    Gibbs P, Anderson C, Pearlman N, LaClaire S, Becker M, Gatlin K, O'Driscoll M, Stephens J, Gonzalez R.
    Cancer; 2002 Jan 15; 94(2):470-6. PubMed ID: 11900232
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.
    Legha SS, Ring S, Eton O, Bedikian A, Buzaid AC, Plager C, Papadopoulos N.
    J Clin Oncol; 1998 May 15; 16(5):1752-9. PubMed ID: 9586888
    [Abstract] [Full Text] [Related]

  • 16. Outpatient chemoimmunotherapy for the treatment of metastatic melanoma.
    Thompson JA, Gold PJ, Fefer A.
    Semin Oncol; 1997 Feb 15; 24(1 Suppl 4):S44-8. PubMed ID: 9122734
    [Abstract] [Full Text] [Related]

  • 17. Combined chemoimmunotherapy of metastatic melanoma: a single institution experience.
    Di Lauro V, Scalone S, La Mura N, Zanetti M, Nigri P, Freschi A, Veronesi A.
    Melanoma Res; 2005 Jun 15; 15(3):209-12. PubMed ID: 15917704
    [Abstract] [Full Text] [Related]

  • 18. A phase II study of interferon-alpha 2b with dacarbazine, carmustine, cisplatin and tamoxifen in metastatic melanoma.
    Schultz MZ, Buzaid AC, Poo WJ.
    Melanoma Res; 1997 Apr 15; 7(2):147-51. PubMed ID: 9167181
    [Abstract] [Full Text] [Related]

  • 19. Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma).
    Sertoli MR, Queirolo P, Bajetta E, Del Vecchio M, Comella G, Barduagni L, Bernengo MG, Vecchio S, Criscuolo D, Bufalino R, Morabito A, Cascinelli N.
    Melanoma Res; 1999 Oct 15; 9(5):503-9. PubMed ID: 10596917
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.